Related Experiment Video

Updated: Apr 12, 2026

Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model
10:32

Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model

Published on: April 2, 2021

4.5K

Polymorphisms of Vascular Endothelial Growth Factor and Retinopathy of Prematurity

Aliaa A Ali, Nouran F Hussien, Rania M Samy

    Journal of Pediatric Ophthalmology and Strabismus
    |May 21, 2015
    PubMed

    Insights

    The VEGF 634 C/G gene variant is linked to an increased risk of retinopathy of prematurity (ROP) in preterm infants. This genetic marker, along with clinical factors, may aid in ROP screening.

    Area of Science:

    • Ophthalmology
    • Genetics
    • Neonatology

    Background:

    • Retinopathy of prematurity (ROP) is a significant cause of vision impairment in premature infants.
    • Retinal neovascularization in ROP is influenced by factors like vascular endothelial growth factor (VEGF).

    Purpose of the Study:

    • To investigate the association between VEGF gene polymorphisms and ROP in preterm infants.
    • To identify clinical risk factors for ROP in a neonatal intensive care unit population.

    Main Methods:

    • Genotyping of VEGF 634 C/G and 936 C/T polymorphisms using PCR-RFLP in 102 preterm infants.
    • Logistic regression analysis to determine significant risk factors for ROP.

    Main Results:

    • The VEGF 634 CG genotype was more frequent in infants with ROP.
    • Low birth weight, maternal disease, respiratory distress syndrome, hypotension, and the VEGF 634 CG genotype were significant ROP risk factors.
    • VEGF 634 G allele distribution differed significantly between ROP and control groups.

    Conclusions:

    • The VEGF 634 C/G polymorphism carrier state impacts ROP risk in infants.
    • VEGF 634 C/G may serve as a potential screening marker for ROP in high-risk infants.
    Abstract

    More Related Videos

    Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts05:56

    Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts

    Published on: January 22, 2020

    5.3K
    Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies12:28

    Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies

    Published on: March 12, 2022

    4.5K

    Related Concept Videos

    Regulation of Angiogenesis and Blood Supply01:24

    Regulation of Angiogenesis and Blood Supply

    Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
    4.0K
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    69
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    125
    The Retinoblastoma Gene01:20

    The Retinoblastoma Gene

    Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
    The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
    5.0K